It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its treatment that tunes gene activity within the body. Why it matters: The ...

In less than 36 hours between the evening of Jan. 12 and the morning of Jan. 14, three local life science companies raised a ...

(Tune Photos) Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to ...

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs ...